Have a personal or library account? Click to login
Latest Insights in Alcohol-Related Liver Disease and Alcoholic Hepatitis Cover

Latest Insights in Alcohol-Related Liver Disease and Alcoholic Hepatitis

Open Access
|Apr 2025

References

  1. M. Ventura-Cots, M. P. Ballester-Ferré, S. Ravi, and R. Bataller, “Public health policies and alcohol-related liver disease,” JHEP Rep., vol. 1, no. 5, pp. 403–413, Aug. 2019, doi: 10.1016/j.jhepr.2019.07.009.
  2. M. Hernandez-Tejero, A. Clemente-Sanchez, and R. Bataller, “Spectrum, Screening, and Diagnosis of Alcohol-related Liver Disease,” J. Clin. Exp. Hepatol., vol. 13, no. 1, pp. 75–87, 2023, doi: 10.1016/j.jceh.2022.10.002.
  3. A. K. Singal and P. Mathurin, “Diagnosis and Treatment of Alcohol-Associated Liver Disease: A Review,” JAMA, vol. 326, no. 2, pp. 165–176, Jul. 2021, doi: 10.1001/jama.2021.7683.
  4. N. Hosseini, J. Shor, and G. Szabo, “Alcoholic Hepatitis: A Review,” Alcohol Alcohol. Oxf. Oxfs., vol. 54, no. 4, pp. 408–416, Jul. 2019, doi: 10.1093/alcalc/agz036.
  5. R. Bataller, J. P. Arab, and V. H. Shah, “Alcohol-Associated Hepatitis,” N. Engl. J. Med., vol. 387, no. 26, pp. 2436–2448, Dec. 2022, doi: 10.1056/NEJMra2207599.
  6. E. Rahimi and J.-J. Pan, “Prognostic models for alcoholic hepatitis,” Biomark. Res., vol. 3, p. 20, Jul. 2015, doi: 10.1186/s40364-015-0046-z.
  7. V.-T. Enciu, P. M. Ologeanu, A.-M. Călin-Necula, A. C. Moldoveanu, G. Oprea-Călin, and C. Fierbinţeanu-Braticevici, “Model of disease severity in alcoholic hepatitis and novel prognostic insights,” Romanian J. Intern. Med. Rev. Roum. Med. Interne, vol. 62, no. 2, pp. 194–202, Jun. 2024, doi: 10.2478/rjim-2024-0001.
  8. M. A. Healey et al., “Utility of Lille Score in Predicting 30-Day Survival in Steroid-Treated Alcohol-Associated Hepatitis,” Dig. Dis. Sci., vol. 69, no. 8, pp. 3043–3050, Aug. 2024, doi: 10.1007/s10620-024-08479-6.
  9. L. A. Díaz et al., “MELD 3.0 adequately predicts mortality and renal replacement therapy requirements in patients with alcohol-associated hepatitis,” JHEP Rep. Innov. Hepatol., vol. 5, no. 8, p. 100727, Aug. 2023, doi: 10.1016/j.jhepr.2023.100727.
  10. W. C. Maddrey, J. K. Boitnott, M. S. Bedine, F. L. Weber, E. Mezey, and R. I. White, “Corticosteroid therapy of alcoholic hepatitis,” Gastroenterology, vol. 75, no. 2, pp. 193–199, Aug. 1978.
  11. E. Nguyen-Khac et al., “Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis,” N. Engl. J. Med., vol. 365, no. 19, pp. 1781–1789, Nov. 2011, doi: 10.1056/NEJMoa1101214.
  12. M. Thursz et al., “EASL Clinical Practice Guidelines: Management of alcohol-related liver disease,” J. Hepatol., vol. 69, no. 1, pp. 154–181, Jul. 2018, doi: 10.1016/j.jhep.2018.03.018.
  13. M. E. Rinella et al., “A multisociety Delphi consensus statement on new fatty liver disease nomenclature,” J. Hepatol., vol. 79, no. 6, pp. 1542–1556, Dec. 2023, doi: 10.1016/j.jhep.2023.06.003.
  14. “Hepahealth II,” EASL-The Home of Hepatology. Accessed: Dec. 02, 2024. [Online]. Available: https://easl.eu/hepahealth-ii/
  15. M. A. Avila et al., “Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting,” Gut, vol. 69, no. 4, pp. 764–780, Apr. 2020, doi: 10.1136/gutjnl-2019-319720.
  16. “Alcohol’s Effects on the Body | National Institute on Alcohol Abuse and Alcoholism (NIAAA).” Accessed: Jan. 28, 2025. [Online]. Available: https://www.niaaa.nih.gov/alcohols-effects-health/alcohols-effects-body
  17. M. Roerecke et al., “Alcohol Consumption and Risk of Liver Cirrhosis: A Systematic Review and Meta-Analysis,” Am. J. Gastroenterol., vol. 114, no. 10, pp. 1574–1586, Oct. 2019, doi: 10.14309/ajg.0000000000000340.
  18. “2023 NSDUH Detailed Tables | CBHSQ Data.” Accessed: Jan. 28, 2025. [Online]. Available: https://www.samhsa.gov/data/report/2023-nsduh-detailed-tables
  19. R. F. Simpson et al., “Alcohol drinking patterns and liver cirrhosis risk: analysis of the prospective UK Million Women Study,” Lancet Public Health, vol. 4, no. 1, pp. e41–e48, Jan. 2019, doi: 10.1016/S2468-2667(18)30230-5.
  20. N. Torp et al., “Binge drinking induces an acute burst of markers of hepatic fibrogenesis (PRO-C3),” Liver Int. Off. J. Int. Assoc. Study Liver, vol. 42, no. 1, pp. 92–101, Jan. 2022, doi: 10.1111/liv.15120.
  21. U. Becker, M. Grønbaek, D. Johansen, and T. I. A. Sørensen, “Lower risk for alcohol-induced cirrhosis in wine drinkers,” Hepatol. Baltim. Md, vol. 35, no. 4, pp. 868–875, Apr. 2002, doi: 10.1053/jhep.2002.32101.
  22. S. Buch et al., “A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis,” Nat. Genet., vol. 47, no. 12, pp. 1443–1448, Dec. 2015, doi: 10.1038/ng.3417.
  23. J. B. Whitfield et al., “A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers,” J. Hepatol., vol. 76, no. 2, pp. 275–282, Feb. 2022, doi: 10.1016/j.jhep.2021.10.005.
  24. F. Stickel et al., “Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis,” Am. J. Gastroenterol., vol. 113, no. 10, pp. 1475–1483, Oct. 2018, doi: 10.1038/s41395-018-0041-8.
  25. Y. Chang et al., “Low Levels of Alcohol Consumption, Obesity, and Development of Fatty Liver With and Without Evidence of Advanced Fibrosis,” Hepatol. Baltim. Md, vol. 71, no. 3, pp. 861–873, Mar. 2020, doi: 10.1002/hep.30867.
  26. T. B. Peeraphatdit et al., “A Cohort Study Examining the Interaction of Alcohol Consumption and Obesity in Hepatic Steatosis and Mortality,” Mayo Clin. Proc., vol. 95, no. 12, pp. 2612–2620, Dec. 2020, doi: 10.1016/j.mayocp.2020.04.046.
  27. A. Moriya et al., “Roles of alcohol consumption in fatty liver: a longitudinal study,” J. Hepatol., vol. 62, no. 4, pp. 921–927, Apr. 2015, doi: 10.1016/j.jhep.2014.11.025.
  28. F. Åberg, J. Helenius-Hietala, P. Puukka, M. Färkkilä, and A. Jula, “Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population,” Hepatol. Baltim. Md, vol. 67, no. 6, pp. 2141–2149, Jun. 2018, doi: 10.1002/hep.29631.
  29. E. Alvarado-Tapias et al., “Bariatric Surgery Is Associated with Alcohol-Related Liver Disease and Psychiatric Disorders Associated with AUD,” Obes. Surg., vol. 33, no. 5, pp. 1494–1505, May 2023, doi: 10.1007/s11695-023-06490-w.
  30. M.-C. Tsai et al., “Association of Heavy Alcohol Intake and ALDH2 rs671 Polymorphism With Hepatocellular Carcinoma and Mortality in Patients With Hepatitis B Virus–Related Cirrhosis,” JAMA Netw. Open, vol. 5, no. 7, p. e2223511, Jul. 2022, doi: 10.1001/jamanetworkopen.2022.23511.
  31. L. Llamosas-Falcón et al., “Impact of alcohol on the progression of HCV-related liver disease: A systematic review and meta-analysis,” J. Hepatol., vol. 75, no. 3, pp. 536–546, Sep. 2021, doi: 10.1016/j.jhep.2021.04.018.
  32. L. M. Fletcher, J. L. Dixon, D. M. Purdie, L. W. Powell, and D. H. G. Crawford, “Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis,” Gastroenterology, vol. 122, no. 2, pp. 281–289, Feb. 2002, doi: 10.1053/gast.2002.30992.
  33. C. Yan, W. Hu, J. Tu, J. Li, Q. Liang, and S. Han, “Pathogenic mechanisms and regulatory factors involved in alcoholic liver disease,” J. Transl. Med., vol. 21, no. 1, p. 300, May 2023, doi: 10.1186/s12967-023-04166-8.
  34. D. Zhang, Z. Liu, and F. Bai, “Roles of Gut Microbiota in Alcoholic Liver Disease,” Int. J. Gen. Med., vol. 16, pp. 3735–3746, Aug. 2023, doi: 10.2147/IJGM.S420195.
  35. C. Martino et al., “Acetate reprograms gut microbiota during alcohol consumption,” Nat. Commun., vol. 13, no. 1, p. 4630, Aug. 2022, doi: 10.1038/s41467-022-31973-2.
  36. L. Zhu, Y. Wang, C. Q. Pan, and H. Xing, “Gut microbiota in alcohol-related liver disease: pathophysiology and gut-brain cross talk,” Front. Pharmacol., vol. 14, p. 1258062, Aug. 2023, doi: 10.3389/fphar.2023.1258062.
  37. S. Lang et al., “Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis,” Hepatol. Baltim. Md, vol. 71, no. 2, pp. 522–538, Feb. 2020, doi: 10.1002/hep.30832.
  38. Y. Gao et al., “Porphyromonas gingivalis exacerbates alcoholic liver disease by altering gut microbiota composition and host immune response in mice,” J. Clin. Periodontol., vol. 50, no. 9, pp. 1253–1263, Sep. 2023, doi: 10.1111/jcpe.13833.
  39. S. Roychowdhury, B. Glueck, Y. Han, M. A. Mohammad, and G. A. M. Cresci, “A Designer Synbiotic Attenuates Chronic-Binge Ethanol-Induced Gut-Liver Injury in Mice,” Nutrients, vol. 11, no. 1, p. 97, Jan. 2019, doi: 10.3390/nu11010097.
  40. Q. Wang et al., “Microbial treatment of alcoholic liver disease: A systematic review and meta-analysis,” Front. Nutr., vol. 9, p. 1054265, 2022, doi: 10.3389/fnut.2022.1054265.
  41. A. Ajoolabady, H. Aslkhodapasandhokmabad, Y. Zhou, and J. Ren, “Epigenetic modification in alcohol-related liver diseases,” Med. Res. Rev., vol. 42, no. 4, pp. 1463–1491, Jul. 2022, doi: 10.1002/med.21881.
  42. D. Stols-Gonçalves et al., “Metabolic Dysfunction-Associated Steatotic Liver Disease and Alcohol-Associated Liver Disease: Liver DNA Methylation Analysis—A Systematic Review,” Cells, vol. 13, no. 22, p. 1893, Nov. 2024, doi: 10.3390/cells13221893.
  43. A. Lawan and A. M. Bennett, “Mitogen-Activated Protein Kinase Regulation in Hepatic Metabolism,” Trends Endocrinol. Metab. TEM, vol. 28, no. 12, pp. 868–878, Dec. 2017, doi: 10.1016/j.tem.2017.10.007.
  44. P. Melgar-Lesmes, M. Perramon, and W. Jiménez, “Roles of the Hepatic Endocannabinoid and Apelin Systems in the Pathogenesis of Liver Fibrosis,” Cells, vol. 8, no. 11, p. 1311, Oct. 2019, doi: 10.3390/cells8111311.
  45. Q. Cai, C. Gan, C. Tang, H. Wu, and J. Gao, “Mechanism and Therapeutic Opportunities of Histone Modifications in Chronic Liver Disease,” Front. Pharmacol., vol. 12, p. 784591, Nov. 2021, doi: 10.3389/fphar.2021.784591.
  46. N. J. Shah, A. Royer, and S. John, “Alcoholic Hepatitis,” in StatPearls, Treasure Island (FL): StatPearls Publishing, 2023. Accessed: Aug. 30, 2023. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK470217/
  47. M. Bou Saleh et al., “Loss of hepatocyte identity following aberrant YAP activation: A key mechanism in alcoholic hepatitis,” J. Hepatol., vol. 75, no. 4, pp. 912–923, Oct. 2021, doi: 10.1016/j.jhep.2021.05.041.
  48. D. Blaya et al., “Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation,” Gut, vol. 65, no. 9, pp. 1535–1545, Sep. 2016, doi: 10.1136/gutjnl-2015-311314.
  49. M. Jouve, R. Carpentier, S. Kraiem, N. Legrand, and C. Sobolewski, “MiRNAs in Alcohol-Related Liver Diseases and Hepatocellular Carcinoma: A Step toward New Therapeutic Approaches?,” Cancers, vol. 15, no. 23, p. 5557, Nov. 2023, doi: 10.3390/cancers15235557.
  50. J. Chen et al., “MicroRNA-30a ameliorates hepatic fibrosis by inhibiting Beclin1-mediated autophagy,” J. Cell. Mol. Med., vol. 21, no. 12, pp. 3679–3692, Dec. 2017, doi: 10.1111/jcmm.13278.
  51. P. Saikia et al., “Hyaluronic acid 35 normalizes TLR4 signaling in Kupffer cells from ethanol-fed rats via regulation of microRNA291b and its target Tollip,” Sci. Rep., vol. 7, no. 1, p. 15671, Nov. 2017, doi: 10.1038/s41598-017-15760-4.
  52. H. Chaudhry, A. Sohal, H. Iqbal, and M. Roytman, “Alcohol-related hepatitis: A review article,” World J. Gastroenterol., vol. 29, no. 17, pp. 2551–2570, May 2023, doi: 10.3748/wjg.v29.i17.2551.
  53. R. Jalan et al., “Toward an improved definition of acute-on-chronic liver failure,” Gastroenterology, vol. 147, no. 1, pp. 4–10, Jul. 2014, doi: 10.1053/j.gastro.2014.05.005.
  54. M. P. Ballester, R. Sittner, and R. Jalan, “Alcohol and Acute-on-Chronic Liver Failure,” J. Clin. Exp. Hepatol., vol. 12, no. 5, pp. 1360–1370, 2022, doi: 10.1016/j.jceh.2021.12.010.
  55. V. Rachakonda, R. Bataller, and A. Duarte-Rojo, “Recent advances in alcoholic hepatitis,” F1000Research, vol. 9, p. F1000 Faculty Rev-97, Feb. 2020, doi: 10.12688/f1000research.20394.1.
  56. L. L. Jophlin et al., “ACG Clinical Guideline: Alcohol-Associated Liver Disease,” Am. J. Gastroenterol., vol. 119, no. 1, pp. 30–54, Jan. 2024, doi: 10.14309/ajg.0000000000002572.
  57. C. L. Mendenhall, S. Anderson, R. E. Weesner, S. J. Goldberg, and K. A. Crolic, “Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis,” Am. J. Med., vol. 76, no. 2, pp. 211–222, Feb. 1984, doi: 10.1016/0002-9343(84)90776-9.
  58. V.-T. Enciu, P. M. Ologeanu, and C. Fierbinteanu-Braticevici, “Ultrasound Assessment of Sarcopenia in Alcoholic Liver Disease,” Diagn. Basel Switz., vol. 14, no. 17, p. 1891, Aug. 2024, doi: 10.3390/diagnostics14171891.
  59. K. Seppä, P. Laippala, and M. Saarni, “Macrocytosis as a consequence of alcohol abuse among patients in general practice,” Alcohol. Clin. Exp. Res., vol. 15, no. 5, pp. 871–876, Oct. 1991, doi: 10.1111/j.1530-0277.1991.tb00615.x.
  60. H. I. Lim and A. Cuker, “Thrombocytopenia and liver disease: pathophysiology and periprocedural management,” Hematol. Am. Soc. Hematol. Educ. Program, vol. 2022, no. 1, p. 296, Dec. 2022, doi: 10.1182/hematology.2022000408.
  61. A. Louvet et al., “Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids,” J. Hepatol., vol. 48, no. 3, pp. 465–470, Mar. 2008, doi: 10.1016/j.jhep.2007.10.010.
  62. D. W. CRABB et al., “Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia,” Gastroenterology, vol. 150, no. 4, pp. 785–790, Apr. 2016, doi: 10.1053/j.gastro.2016.02.042.
  63. J. Altamirano et al., “A histologic scoring system for prognosis of patients with alcoholic hepatitis,” Gastroenterology, vol. 146, no. 5, pp. 1231–1239.e1–6, May 2014, doi: 10.1053/j.gastro.2014.01.018.
  64. M. Lupşor-Platon et al., “Noninvasive assessment of liver steatosis using ultrasound methods,” Med. Ultrason., vol. 16, no. 3, pp. 236–245, Sep. 2014, doi: 10.11152/mu.2013.2066.163.1mlp.
  65. S. Maheshwari et al., “Imaging of Alcohol-Associated Liver Disease,” Am. J. Roentgenol., vol. 222, no. 1, p. e2329917, Jan. 2024, doi: 10.2214/AJR.23.29917.
  66. F. Janssens, N. de Suray, H. Piessevaux, Y. Horsmans, P. de Timary, and P. Stärkel, “Can transient elastography replace liver histology for determination of advanced fibrosis in alcoholic patients: a real-life study,” J. Clin. Gastroenterol., vol. 44, no. 8, pp. 575–582, Sep. 2010, doi: 10.1097/MCG.0b013e3181cb4216.
  67. A. Louvet et al., “The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids,” Hepatol. Baltim. Md, vol. 45, no. 6, pp. 1348–1354, Jun. 2007, doi: 10.1002/hep.21607.
  68. E. H. Forrest et al., “The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids,” Gut, vol. 56, no. 12, pp. 1743–1746, Dec. 2007, doi: 10.1136/gut.2006.099226.
  69. M. Sheth, M. Riggs, and T. Patel, “Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis,” BMC Gastroenterol., vol. 2, p. 2, 2002, doi: 10.1186/1471-230x-2-2.
  70. W. Dunn et al., “MELD accurately predicts mortality in patients with alcoholic hepatitis,” Hepatol. Baltim. Md, vol. 41, no. 2, pp. 353–358, Feb. 2005, doi: 10.1002/hep.20503.
  71. S. R. Atkinson et al., “In Severe Alcoholic Hepatitis, Serum Keratin-18 Fragments Are Diagnostic, Prognostic, and Theragnostic Biomarkers,” Off. J. Am. Coll. Gastroenterol. ACG, vol. 115, no. 11, p. 1857, Nov. 2020, doi: 10.14309/ajg.0000000000000912.
  72. J. Bissonnette et al., “A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis,” Hepatol. Baltim. Md, vol. 66, no. 2, pp. 555–563, Aug. 2017, doi: 10.1002/hep.29080.
  73. S. R. Atkinson et al., “Serum keratin 19 (CYFRA21-1) is a prognostic biomarker in severe alcoholic hepatitis,” Liver Int. Off. J. Int. Assoc. Study Liver, vol. 42, no. 5, pp. 1049–1057, May 2022, doi: 10.1111/liv.15218.
  74. A. Louvet et al., “Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: A prospective study,” Hepatol. Baltim. Md, vol. 66, no. 5, pp. 1464–1473, Nov. 2017, doi: 10.1002/hep.29240.
  75. R. Liang, A. Liu, R. B. Perumpail, R. J. Wong, and A. Ahmed, “Advances in alcoholic liver disease: An update on alcoholic hepatitis,” World J. Gastroenterol., vol. 21, no. 42, p. 11893, Nov. 2015, doi: 10.3748/wjg.v21.i42.11893.
  76. J. Altamirano et al., “Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: Prediction and impact on long-term survival,” Hepatol. Baltim. Md, vol. 66, no. 6, pp. 1842–1853, Dec. 2017, doi: 10.1002/hep.29338.
  77. H. L. Bonkovsky et al., “A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. II. Short-term effects on nitrogen metabolism, metabolic balance, and nutrition,” Am. J. Gastroenterol., vol. 86, no. 9, pp. 1209–1218, Sep. 1991.
  78. A. M. Diehl et al., “Effect of parenteral amino acid supplementation in alcoholic hepatitis,” Hepatol. Baltim. Md, vol. 5, no. 1, pp. 57–63, 1985, doi: 10.1002/hep.1840050114.
  79. C. Mendenhall, G. A. Roselle, P. Gartside, and T. Moritz, “Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration Cooperative Studies,” Alcohol. Clin. Exp. Res., vol. 19, no. 3, pp. 635–641, Jun. 1995, doi: 10.1111/j.1530-0277.1995.tb01560.x.
  80. S. C. Bischoff et al., “ESPEN practical guideline: Clinical nutrition in liver disease,” Clin. Nutr. Edinb. Scotl., vol. 39, no. 12, pp. 3533–3562, Dec. 2020, doi: 10.1016/j.clnu.2020.09.001.
  81. G. Szabo et al., “IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis,” Hepatol. Baltim. Md, vol. 76, no. 4, pp. 1058–1068, Oct. 2022, doi: 10.1002/hep.32478.
  82. A. Dhanda et al., “Trace element deficiency is highly prevalent and associated with infection and mortality in patients with alcoholic hepatitis,” Aliment. Pharmacol. Ther., vol. 52, no. 3, pp. 537–544, Aug. 2020, doi: 10.1111/apt.15880.
  83. S. Støy, T. L. Laursen, L. L. Eriksen, H. Grønbæk, H. Vilstrup, and T. D. Sandahl, “No Effect in Alcoholic Hepatitis of Gut-Selective, Broad-Spectrum Antibiotics on Bacterial Translocation or Hepatic and Systemic Inflammation,” Clin. Transl. Gastroenterol., vol. 12, no. 2, p. e00306, Jan. 2021, doi: 10.14309/ctg.0000000000000306.
  84. C. Rongey and N. Kaplowitz, “Current concepts and controversies in the treatment of alcoholic hepatitis,” World J. Gastroenterol. WJG, vol. 12, no. 43, pp. 6909–6921, Nov. 2006, doi: 10.3748/wjg.v12.i43.6909.
  85. S. M. Shasthry and S. K. Sarin, “New treatment options for alcoholic hepatitis,” World J. Gastroenterol., vol. 22, no. 15, pp. 3892–3906, Apr. 2016, doi: 10.3748/wjg.v22.i15.3892.
  86. S. Singh et al., “Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis: A Systematic Review and Network Meta-analysis,” Gastroenterology, vol. 149, no. 4, pp. 958–970.e12, Oct. 2015, doi: 10.1053/j.gastro.2015.06.006.
  87. G. Szabo et al., “IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis,” Hepatol. Baltim. Md, vol. 76, no. 4, pp. 1058–1068, Oct. 2022, doi: 10.1002/hep.32478.
  88. S. Gawrieh et al., “Randomized trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis,” J. Hepatol., vol. 80, no. 5, pp. 684–693, May 2024, doi: 10.1016/j.jhep.2024.01.031.
  89. A. Marot, A. K. Singal, C. Moreno, and P. Deltenre, “Granulocyte colony-stimulating factor for alcoholic hepatitis: A systematic review and meta-analysis of randomised controlled trials,” JHEP Rep., vol. 2, no. 5, p. 100139, Jun. 2020, doi: 10.1016/j.jhepr.2020.100139.
  90. A. Louvet et al., “Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study,” Lancet Gastroenterol. Hepatol., vol. 7, no. 5, pp. 416–425, May 2022, doi: 10.1016/S2468-1253(21)00430-1.
  91. B. P. Lee et al., “Patterns of Alcohol Use After Early Liver Transplantation for Alcoholic Hepatitis,” Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc., vol. 20, no. 2, pp. 409–418.e5, Feb. 2022, doi: 10.1016/j.cgh.2020.11.024.
  92. C. A. Marroni et al., “Liver transplantation and alcoholic liver disease: History, controversies, and considerations,” World J. Gastroenterol., vol. 24, no. 26, pp. 2785–2805, Jul. 2018, doi: 10.3748/wjg.v24.i26.2785.
  93. R. Bañares et al., “Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial,” Hepatol. Baltim. Md, vol. 57, no. 3, pp. 1153–1162, Mar. 2013, doi: 10.1002/hep.26185.
  94. S. E. Kumar et al., “Low Volume Plasma Exchange and Low Dose Steroid Improve Survival in Patients With Alcohol-Related Acute on Chronic Liver Failure and Severe Alcoholic Hepatitis - Preliminary Experience,” J. Clin. Exp. Hepatol., vol. 12, no. 2, pp. 372–378, 2022, doi: 10.1016/j.jceh.2021.07.010.
  95. A. Pande et al., “Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial,” Hepatol. Int., vol. 17, no. 1, pp. 249–261, Feb. 2023, doi: 10.1007/s12072-022-10438-0.
  96. Z. DeFilipp et al., “Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant,” N. Engl. J. Med., vol. 381, no. 21, pp. 2043–2050, Nov. 2019, doi: 10.1056/NEJMoa1910437.
  97. J. H. Jung, S.-E. Kim, K. T. Suk, and D. J. Kim, “Gut microbiota-modulating agents in alcoholic liver disease: Links between host metabolism and gut microbiota,” Front. Med., vol. 9, Jul. 2022, doi: 10.3389/fmed.2022.913842.
DOI: https://doi.org/10.2478/rjim-2025-0007 | Journal eISSN: 2501-062X | Journal ISSN: 1220-4749
Language: English
Page range: 97 - 106
Submitted on: Feb 18, 2025
Published on: Apr 17, 2025
Published by: N.G. Lupu Internal Medicine Foundation
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2025 Vlad-Teodor Enciu, Priscila Mădălina Ologeanu, Alexandru Constantinescu, Carmen Fierbinteanu-Braticevici, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.